Lexington, United States
LogicBio Therapeutics, founded in 2015 and headquartered in the United States, is at the forefront of biotechnology innovation with its pioneering approach to gene therapy. Known for its slogan, "Develops gene therapy vectors for previously incurable genetic and infectious diseases including hemophilia, HIV/AIDS, and methylmalonic acidemia," the company has focused on treating rare pediatric conditions.
Their trademarked technology, GeneRide™, represents a breakthrough in genome editing. This promoterless and nuclease-free method facilitates site-specific integration of therapeutic genes into the genome, enhancing the safety profile of AAV based therapies. This allows for durable gene expression limited to specific cell types, offering a safer therapeutic approach.
In terms of the investment trajectory, LogicBio was acquired by Alexion, AstraZeneca Rare Disease, with its last investment noted as an acquisition investment on 01 October 2022 by Ionis Pharmaceuticals.
